Shots:

• The EC approval is based on a P-III QUAZAR AML-001 study assessing Onureg (300mg- qd) vs PBO + BSC for 14days of a 28-day cycle in patients aged ≥55yrs. with AML who achieved CR or with CRi following induction therapy with/out consolidation treatment and who are not candidates for- including those who choose not to proceed to HSCT
• The study showed 1EPs of OS is greater than 2yrs. (24.7mos. vs 14.8mos.)- mDOR (12 vs 6 cycles); m- relapse-free survival (10.2 vs 4.8 mos.)
• Onureg is the first and only once-daily- frontline oral maintenance therapy in the EU for patients with a broad range of AML subtypes

  Ref: BMS | Image: BMS